Identification of Discrete Prognostic Groups in Ewing Sarcoma
Open Access
- 10 August 2015
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 63 (1) , 47-53
Abstract
Background: Although multiple prognostic variables have been proposed for Ewing sarcoma (EWS), little work has been done to further categorize these variables into prognostic groups for risk classification.Procedure: We derived initial prognostic groups from 2,124 patients with EWS in the SEER database. We constructed a multivariable recursive partitioning model of overall survival using the following covariates: age; stage; race/ethnicity; sex; axial primary; pelvic primary; and bone or soft tissue primary. Based on this model, we identified risk groups and estimated 5‐year overall survival for each group using Kaplan–Meier methods. We then applied these groups to 1,680 patients enrolled on COG clinical trials.Results: A multivariable model identified five prognostic groups with significantly different overall survival: (i) localized, age P < 0.0001). A sub‐analysis of COG patients treated with ifosfamide and etoposide as a component of therapy evaluated these findings in patients receiving contemporary therapy.Conclusions: Recursive partitioning analysis yields discrete prognostic groups in EWS that provide valuable information for patients and clinicians in determining an individual patient's risk of death. These groups may enable future clinical trials to adjust EWS treatment according to individualized risk. Pediatr Blood CancerKeywords
Funding Information
- NIH/NCI (1K23CA154530)
- NIH T32 Training (5T32CA128583-05)
- Campini Foundation
- Alex's Lemonade Stand Foundation
- COG Chair's (CA98543-08)
- COG Statistics and Data Center (CA98413-08)
- Nick Currey Foundation at CureSearch for Children's Cancer
- Daniel P. Sullivan Fund
This publication has 28 references indexed in Scilit:
- Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosisCancer Epidemiology, 2013
- A pilot study of low‐dose anti‐angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893Pediatric Blood & Cancer, 2012
- Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 TrialJournal of Clinical Oncology, 2010
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60Cancer, 2007
- Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of BoneNew England Journal of Medicine, 2003
- Residual‐based tree‐structured survival analysisStatistics in Medicine, 2001
- High-Dose Melphalan, Etoposide, Total-Body Irradiation, and Autologous Stem-Cell Reconstitution as Consolidation Therapy for High-Risk Ewing’s Sarcoma Does Not Improve PrognosisJournal of Clinical Oncology, 2001
- Adults With Ewing’s Sarcoma/Primitive Neuroectodermal TumorAnnals of Surgery, 1999
- Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: The CESS 86 experienceMedical and Pediatric Oncology, 1999